His FGFR2-CEP55 fusion VAF was 3.9% when starting infigratinib, became undetectable after 4 weeks, remained undetectable for 23 weeks, and then slowly increased to 2.9% when treatment was stopped due to the emergence of corneal ulcers. This evidence concerns the gene FGFR2 and corneal ulcer.